The monoclonal antibody targeting FAP (sibrutuzumab) and the small molecule inhibitors of FAP (F19 and PT100) were well‐tolerated, but no obvious clinical anti‐tumor effect was observed in Phase I clinical trials, and subsequent structural adjustments may be needed.345, 346, 347. The gene discussed is FAP; the disease is neoplasm.